HECT and RLD domain containing E3 ubiquitin protein ligase 5Genealiases: CEB1 · CEBP1
Q-omics provides the consensus-scored HERC5 profile across patient tissues and cancer cell-line models. HERC5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HERC5 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, HERC5 RNA expression shows 18,350 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, HNSC, and UVM as cancer lineages where HERC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HERC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HERC5 survival associations across molecular data types. HERC5 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HERC5 RNA expression–survival associations across cancer types. High HERC5 expression shows unfavorable associations in UCEC and LGG, but favorable associations in KIRC, UCS, CESC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for HERC5 RNA expression.
This table summarizes HERC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HERC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HERC5 shows lower tumor expression in KIRP, UCEC, KICH, COAD and LIHC and higher tumor expression in HNSC. The HNSC box plot shows higher HERC5 RNA expression in tumor versus normal tissue (log2 FC = +1.793, t-test p < 0.001).
This table shows molecular features associated with HERC5 in patient tissues and cancer cell lines. In patient samples, HERC5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HERC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
